To further augment the therapeutic index of IL-15, several immunocytokines have been developed with additional antibodies that target tumor-associated antigens to specifically redirect IL-15 to TME, or with conjugated antitumor monoclonal antibodies to improve ADCC (antibody-dependent cellular cytotoxicity). This evidence concerns the gene IL15 and neoplasm.